生命科学资讯

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario

Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play

Madrigal pads MASH pipeline with six siRNAs from China's Ribo

Gubra forms venture unit; Galecto's $275M offering

How a closet full of EKG machines illustrates pharma’s clinical trial cost problem

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

Oscar Health expects explosive growth for 2026, but it comes with a risk

Post-Hoc Live: Is biotech’s relationship with the FDA at a breaking point?

William Blair Reaffirms Their Buy Rating on Thermo Fisher (TMO) - The Globe and Mail

FDA Approval Boosts Agilent Technologies (A) Diagnostic Tool - GuruFocus

A protein model designed for space could expand pharma’s definition of ‘druggability’

Tempest Therapeutics outlines plans for acquired CAR T assets

SUDO-550 demonstrates robust efficacy in MS models

Precision Biosciences’ PBGENE-DMD cleared to enter clinic

Brazilian scientists identify new HDAC6 inhibitors

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award - Business Wire

Madison Asset Management LLC Sells 14,089 Shares of Agilent Technologies, Inc. $A - MarketBeat

GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations

Upstream Bio says verekitug delivered positive data in Phase 2 severe asthma trial

FDA refuses to review Moderna’s mRNA flu vaccine